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Abstract: Valerianaceae, the sub-family of Caprifoliaceae, contains more than 300 species of annual
and perennial herbs, worldwide distributed. Several species are used for their biological properties
while some are used as food. Species from the genus Valeriana have been used for their antispasmodic,
relaxing, and sedative properties, which have been mainly attributed to the presence of valepotriates,
borneol derivatives, and isovalerenic acid. Among this genus, the most common and employed
species is Valeriana officinalis. Although valerian has been traditionally used as a mild sedative,
research results are still controversial regarding the role of the different active compounds, the herbal
preparations, and the dosage used. The present review is designed to summarize and critically
describe the current knowledge on the different plant species belonging to Valerianaceae, their
phytochemicals, their uses in the treatment of different diseases with particular emphasis on the
effects on the central nervous system. The available information on this sub-family was collected
from scientific databases up until year 2020. The following electronic databases were used: PubMed,
Scopus, Sci Finder, Web of Science, Science Direct, NCBI, and Google Scholar. The search terms
used for this review included Valerianaceae, Valeriana, Centranthus, Fedia, Patrinia, Nardostachys,
Plectritis, and Valerianella, phytochemical composition, in vivo studies, Central Nervous System,
neuroprotective, antidepressant, antinociceptive, anxiolytic, anxiety, preclinical and clinical studies.
Keywords: Valerianaceae; anxiolytic; sedative; myorelaxant; antidepressant; biological activities;
clinical studies; phytochemicals; valerian
1. Introduction
Valerianaceae, the sub-family of the family Caprifoliaceae (order Dipsacales), contains
about 315 species of annual and perennial herbs, distributed, throughout the world, ex-
cept Australia and New Zealand, usually at high elevations. Achene fruits, absence of
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endosperm, bilaterally symmetric or sporadically asymmetric and sympetalous flowers,
three-carpellate and inferior ovaries, one fertile carpel at maturity, and an anatropous
ovule are the main characteristics of Valerianaceae sub-family species [1]. Valerianaceae
sub-family showed significant diversity in flowers and fruits morphology. Probably, the
most remarkable variation in the morphology of flowers is related to the stamens number
ranging from 4 to 1. Donoghue et al. [2] described a reduction from the ancestral condition
of 4 to 3 stamens in the Valerianaceae core, followed by an additional reduction to two
stamens in Fedia genus and one stamen in Centranthus genus.
The calyx can be completely lacking as in some Valeriana species, reduced to small
teeth as in Fedia and Valerianella, leafy and persistent as in Nardostachys, or pappus-like and
featherly as in some Valeriana species and in Centranthus. The genera of this sub-family in-
clude Valeriana L., Centranthus Lam. and DC., Fedia Gaertn., Patrinia Juss., Nardostachys DC.,
Plectritis (Lindl.) DC., and Valerianella Mill. Phytochemical studies revealed the presence of
sesquiterpenes, valepotriates, alkaloids, flavonoids, organic acids, and their derivatives,
as characteristic classes of constituents in Valerianaceae plants [3–5]. It is generally ac-
cepted that valepotriates are common in Valerianaceae species and are responsible for their
sedative properties. The present review is designed to report the current knowledge on
the plant species that belong to the sub-family Valerianaceae, their phytochemicals, and
their uses in the treatment of several diseases with particular emphasis to the action on
the central nervous system (CNS). All collected data have been obtained from different
databases such as PubMed, Scopus, Sci Finder, Web of Science, Science Direct, NCBI, and
Google Scholar.
2. Habitat, Distribution, and Traditional Uses of Valerianaceae Sub-Family
Valerianaceae species are mainly found around the Northern Hemisphere. Overall,
their distribution matches that of other Dipsacales clades. Even though the Asiatic origin,
actually the center of diversity Valerianaceae sub-family is located in South America,
where several morphological forms, from rosette plants to annual vine-like species to
microphyllous shrubs, are found in different habitats [2,6–8]. Several species of the genus
Valeriana are abundant in the Andes. Peru is the richest country, but there is a high
number of species also in Ecuador, Chile, Colombia, and Argentina [9]. Species present
in northwestern Argentina, and northern Chile are generally inhabitants of the arid zone
and are taxonomically related to species found in the northern Andes [9]. Patrinia species
are principally distributed in China, Korea, Japan, and Siberia. Nardostachys grandiflora DC.
(syn. Nardostachys chinensis and Nardostachys jatamansi) and Nardostachys scrophulariiflora
(syn. Picrorhiza scrophulariiflora) are alpine perennial herbs found only in the Himalayas [10].
Numerous Valerianaceae species have a traditional use. Several species are used for
their biological properties while some species are used as food. Species from the genus
Valeriana have been used for their antispasmodic, relaxing, and sedative properties that
have been mainly attributed to the presence of valepotriates, borneol derivatives, and
isovalerenic acid [11]. Among this genus, the most common and employed species is
Valeriana officinalis L. Its roots have long been traditionally used for their sleep-promoting,
anxiolytic, sedative, and antispasmodic activities [12–14]. In Brazil, it has been used for
its hypnotic, anticonvulsant, and anxiolytic properties [15]. In Europe, V. officinalis is used
for treating anxiety and restlessness; in the United States, it is mainly employed for its
sleep-promoting activity [12].
Patrinia species are commonly used in Asian medicine to treat peri-appendicular
abscesses, dysentery, erysipelas, conjunctival congestion, lung carbuncle, post-partum
disease, and leucorrhea [16]. The young leaves and shoots of Centranthus ruber (L.) DC.
(Valeriana rubra L., commonly known as red valerian, red spur valerian, and spur vale-
rian) are used in Italy as depurative [17]. N. chinensis has been used in some traditional
medicines, including Chinese, Korean, and Ayurvedic medicine to treat epilepsy, hyste-
ria, hyperglycemia, dyslipidemia, headache, stress indigestion, heart palpitations, mental
weakness, cholera, and leprosy [18]. The leaves of Fedia cornucopieae (L.) Gaertn. are eaten
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in southern Italy (Sicily) raw in salads or cooked (browned in oil, fried, in omelets, and
meatballs) [19].
3. Effect on the Central Nervous System
Among Valerianaceae plants, species from the genus Valeriana (e.g., V. officinalis L.,
V. jatamansi Jones, V. fauriei Briq., V. amurensis Smir. ex Kom, V. glechomifolia Meyer, V.
polystachya Smith, etc.) are the most used to treat CNS-related disorders (Table 1). In
the last decades, many studies have validated the traditional uses of these species. V.
officinalis is the most used particularly for its sedative, anticonvulsant, tranquilizing, and
anxiolytic properties. According to the European Medicine Agency, extracts from this
species roots can be used to alleviate mild nervous anxiety and sleep disorders [20]. V.
officinalis is available as an herbal supplement and is extensively utilized to cure anxiety
disorders. Its anxiolytic effects have been studied by different authors using different
models. Hattesohl et al. [21] investigated in vivo the myorelaxant, anxiolytic, sedative,
and antidepressant properties of different extracts from this species. None of the studied
extracts showed myorelaxant or sedative activity up to limit doses of 500 or 1000 mg/kg
b.w. Nevertheless, some extracts showed pronounced anxiolytic activity in the elevated
plus-maze assay and one extract, after subacute treatment, showed anti-depressant activity
in the forced swimming assay, allowing to conclude that the anti-depressant and anxiolytic
effects may contribute to the positive effects of valerian to improve sleep quality.
The effect of oral administration of V. officinalis root extract on physical and psycholog-
ical stress response was investigated in mice by using a communication box [22]. Obtained
data suggested that this extract could suppress stress responses through the modulation
of the changes in the turnover of norepinephrine and serotonin in the amygdala and
hippocampus, and through the control of corticosterone plasma levels.
In a study by Murphy et al. [23] V. officinalis root extract was intraperitoneally admin-
istered to rats and the number of entries and time spent on the open arms of an elevated
plus-maze was evaluated. A reduced anxious behavior was observed in extract-treated rats
in comparison to the control group and valerenic acid was suggested as the main anxiolytic
component in the extract. However, other studies indicate that other constituents, namely
borneol, lignans, and flavonoids, also exhibited anxiolytic and sedative activity [24–26]. In
addition, studies with other Valeriana species containing low amounts of valerenic acid
(e.g., V. edulis) showed similar properties [27].
Table 1. Selected studies reporting the effects of Valerianaceae species on the central nervous system.
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The anticonvulsant effects of various extracts from V. officinalis were investigated
in mice using the temporal lobe epilepsy model showing that administration of aque-
ous extract significantly decreased seizure activity in amygdala-kindled rats [63]. The
anticonvulsant effect of an aqueous extract against clonic seizure threshold induced by
pentylenetetrazole in mice [48]. Using a different mode, adult zebrafish [51], observed that
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ethanol extract noticeably improved the anticonvulsant effect of the anti-epileptic drugs
clonazepam and phenytoin thus benefiting epilepsy treatment.
Derived Neurotrophic Factor (BDNF) has a crucial role in the CNS. The levels of BDNF
must be maintained at an adequate concentration to allow neurotransmission to occur at
an ideal level and prevent several mental diseases. A significant increase in the BDNF
expression compared to control in SH-SY5Y cell lines treated with V. officinalis extract was
observed allowing us to conclude that the antidepressant effects are mostly due to valerenic
acid [64,65].
Yoo et al. [52] investigated the neuroprotective action from V. officinalis root extracts in
gerbils after transient cerebral ischemia. The results revealed that the oral pretreatment
with 100 mg/kg of extract decreased microglial activation and lipid peroxidation protection
against ischemic damage in the hippocampal pyramidal neurons. In another study, the
same root extract (100 mg/kg) and valerenic acid (340 µg/kg) was orally administered
to control mice and aged mice (previously treated with D-galactose) to evaluate their
effects on cell proliferation, memory function, and neuroblast differentiation in the mouse
dentate gyrus [49]. Both enhanced the preferential exploration of new objects (novel object
recognition test) and the escape latency, platform crossings, swimming speeds, and spatial
preference for the target quadrant (Morris water maze test). They also improved cognitive
function, promoted cell proliferation, neuroblast differentiation, and decreased the plasma
corticosterone levels in aged mice.
The neuroprotective properties of V. officinalis extract and its therapeutic potential
for neurological disorders have been reported. The extract showed protective effects
against toxicity induced by rotenone in Drosophila melanogaster [66]. Rotenone is a chemical
substance widely used as a pesticide that acts within the respiratory chain causing oxidative
damage. Animals’ treatment with this substance has been used as a model to study brain
disorders linked with redox imbalance. Amaral de Brito et al. [56] recently observed that
V. officinalis extract has protective effects against in vitro cytotoxicity induced by rotenone
in rat glioma C6 cells, by a novel action on the cortical spreading depression.
The antinociceptive effects of a V. officinalis hydroalcoholic extract were demonstrated
in adult male Balb/c mice [50]. When mice were injected intraperitoneally at the maximum
dose tested (800 mg/kg), the somatic pain was successfully reduced, the antinocicep-
tive activity was clearly expressed, and the number of abdominal writhings significantly
decreased.
Acetylcholinesterase (AchE) inhibitors have been widely recognized as an effective
treatment for Alzheimer’s disease (AD) and AChE inhibitory activity of compounds from
V. officinalis (sesquiterpenes and a monoterpenoid) have been also validated in mice both
in vitro and in vivo [53].
V. jatamansi (synonymous V. wallichii DC.), popularly named as Indian valerian, is
considered as an Asian counterpart for the European V. officinalis, is another important
medicinal plant from the genus Valeriana, broadly recognized for its uses in anxiety, in-
somnia, epilepsy, and hysteria treatment (Nadkarni, 2001). Many studies are reporting the
pharmacological properties of this species including the sedative, tranquilizing and neuro-
protective effect, and its capacity to attenuate stress, anxiety, and depression (Table 1) [67].
The anti-anxiety effect of its ethanol extract was studied on empty bottle-stimulated rats us-
ing the open field and the elevated plus-maze tests. Four bioactive compounds (hesperidin,
isochlorogenic acid A, isochlorogenic acid B, and isochlorogenic acid C) were identified as
the chemical markers for that effect [46]. There are some reports about the antidepressant
effect of extracts and essential oils from this species [60,68–70]. The nitric oxide pathway is
involved in the antidepressant properties of essential oil from a chemotype of this species
in mice [60]. The essential oil components inhibit nitric oxide to a critical concentration
changing the vesicular release of norepinephrine and serotonin, two neurotransmitters
implicated in depression.
An aqueous roots extract of V. jatamansi was also investigated for its effects on the sleep
pattern of Sprague-Dawley rats by analyzing sleep-wake profile, electroencephalogram
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delta action during sleep, and estimating regional brain monoamines [61]. The extract
ameliorated sleep disturbances and improved sleep quality, which can be related to the
modulation of regional brain monoamines.
Several reports are describing the neuroprotective effects of extracts and compounds
from V. jatamansi [43,62]. The neuroprotective effects of bakkenolides and iridoids against
1-methyl-4-phenylpyridinium (MPP+)-induced neuronal cell death in human dopamin-
ergic neuroblastoma SH-SY5Y cells were demonstrated [43,44]. 1-Metil-4-fenil-1,2,3,6-
tetraidropiridine (MPTP), a precursor of the neurotoxin MPP+, is widely used to study PD
insult. The neuroprotective effects against MPTP in mice by mitigating oxidative stress and
inflammatory damage were also reported [62].
V. fauriei is also described as an antidepressant [37], vasorelaxant [71], and anxi-
olytic [72]. Yoon et al. [34] demonstrated its antinociceptive effects in a fibromyalgia
animal model provoked by intermittent cold stress. Its effects in reducing the occurrence of
prenatal depression and schizophrenia in rats were also reported [38].
V. amurensis (roots and rhizomes) has been extensively employed in Chinese medicine
for the treatment of neurological disorders. The petroleum ether extract improves sleep
by reducing the sleep latency and delaying the sleep duration of mice [73]. Using human
cell lines and mice models Wu et al. [36] recently reported the anti-inflammatory and
neuroprotective properties of kissoone B and extracts of this species, suggesting its capacity
for neurological diseases treatment.
Nardostachys jatamansi (D. Don) DC. (synonymous Nardostachys chinensis Batalin) be-
longs to a different Valerianaceae genus and has also been extensively reported as affecting
CNS disorders (Table 1). The anti-stress properties of this species have been investigated
by several authors and using different animal models. Lyle et al. [74] using a rat model of
chronic fatigue syndrome, observed a significant reversion of the locomotor activity and
the anxiety state in stressed animals, after the oral administration of the extract (200 and
500 mg/kg b.w.). The extract showed the capacity to manage lipid peroxidation, nitrite,
superoxide dismutase, and catalase activities indicating that the antioxidant properties of
this extract can be responsible for its anti-stress effects. Later, Lyle et al. [30] used a cold
restraint stress model to investigate the biochemical and neurochemical alterations induced
by oral administration of a hydro-ethanolic extract in the same doses and observed alter-
ations on rats enzymatic and non-enzymatic antioxidant system, and alleviated oxidative
stress and neurochemical alterations induced by cold restraint stress.
This species has been traditionally used as a tranquilizer and sedative agent and many
investigations demonstrating its anxiolytic and sedative properties. The sedative effect of
extracts and isolated compounds applied by inhalation were previously reported [28,75,76].
Takemoto et al. [76] investigated the sedative effects of oxygenated compounds applied by
inhalation in an excitatory mouse model treated with caffeine and showed that aristolen-
1(10)-en-9-ol exerted its effects via the GABAergic system. The anxiolytic effects of N. jata-
mansi extract were investigated after oral administration to mice (250 mg/kg) by using
different behavioral tests, such as elevated plus maze, light-dark box test, open field test,
and Vogel’s conflict test [32]. A 7 days treatment with the extract showed significant
anxiolytic effects and increased levels of brain monoamine and GABA neurotransmit-
ter, suggesting that anxiolytic effects are mediated by activating the GABAergic receptor
complex.
Recently, the potential of some Nardostachys species to alleviate AD-like symptoms in
Caenorhabditis elegans AD pathological model was investigated and some compounds can
delay AD worm paralysis [29,77].
Some reports are describing the serotonin transporter regulating the activity of com-
pounds from Nardostachys species, like sesquiterpenoids and nardonaphthalenones [78,79].
Serotonin transporter is responsible for the reuptake of 5-hydroxytryptamine into presy-
naptic neurons and plays an important role in the pathophysiology of neuropsychiatric
conditions, like depression, anxiety, or obsessive-compulsive disorder.
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Many investigations have been performed in animals to assess the anticonvulsant
properties of N. chinensis. An ethanol extract significantly increased the seizure threshold in
a dose and time-dependent manner in a rats’ model of electric shock-induced seizures [80].
The anticonvulsant effect of N. jatamansi extract (400 mg/kg b.w.) in a maximal electric
shock model was less than that of the standard sodium valproate (300 mg/kg b.w.) [81].
The neuroprotective effect of an ethanol extract from the roots of this species against Aβ
toxicity was studied in vitro using a cell culture system and in vivo using a Drosophila
AD model [82] and the results suggest that the neuroprotective effect observed can be
linked with the extract antioxidant and anti-inflammatory properties and its inhibitory
effect against extracellular-signal-regulated kinase signaling. Indeed, several extracts,
fractions, and compounds from this species exhibited anti-neuro inflammatory by different
mechanisms [31–34,83,84].
4. Molecular Mechanism of Action of Pharmacological Potential
V. officinalis extracts are one of the most popular herbal medications used to alleviate
insomnia, anxiety, epilepsy, and other conditions of the CNS. Several studies have been
conducted to clarify the mechanisms implicated in the pharmacological effects of these
extracts. γ-Aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the
CNS. GABA is crucial for normal brain function and a reduction in its concentration
has been associated with several neurological conditions as is the case of epilepsy, AD,
Parkinson’s disease, Huntington’s disease, etc. If GABA balance is perturbed, conditions
like depression, sedation, anxiety, restlessness, and insomnia may also arise [85]. Due
to the blood–brain barrier, GABA cannot be easily introduced into the CNS, thus the
inhibition of GABA aminotransferase, the enzyme responsible for its degradation, has been
the target for the adjustment of GABA amounts in the CNS. The mode of action of valerian
compounds is associated with the modulation of GABAergic transmission via inhibition of
GABA transaminase, interaction with GABA receptor/benzodiazepine, and intervention
in uptake and intake of GABA in synaptosomes.
Studies with animal showed that V. officinalis potentiates the GABAergic neuronal
transmission in the brain via the improvement of GABA release and inhibition of the
degradation of GABA via the inhibition of GABA-transaminase [86–88]. A recent study of
molecular docking and molecular dynamics simulation suggests that valerian compounds
could be valuable resources for the development of GABA-transaminase inhibitors [55].
Valle-Mojica et al. [89] suggested an interaction with glutamatergic receptors as a possible
mechanism by which valerian exhibit its action in the central nervous system. Valerian
compounds like valerenic acid and valerenol also displayed allosteric modulation of GABA
receptors [90,91]. In vitro studies indicated that both the activation of adenosine A1 receptor
and GABAA receptors separately contribute to the valerian capacity to induce sleep [92]. It
was also observed that factors like solvent extraction and the stability of the extract affect
the selectivity for the interactions for glutamate receptors [93].
Recently Li et al. [47] demonstrated that the antidepressant activity of the iridoid-rich
fraction from V. jatamansi in a chronic unpredictable mild stress mouse model is exerted
by regulating several metabolic pathways such as the synthesis of neurotransmitters, the
tricarboxylic acid cycle, and amino acid metabolism. Recent studies also using the same
model indicated that that gut flora structures and regulation of serotonin, norepinephrine,
substance P, and corticotropin-releasing factor in the brain and intestine, can be implicated
in the antidepressant properties of this plant [94]. The enhancement of noradrenergic
and/or dopaminergic transmission induced by valepotriates from this species in the mouse
brain can be related to the facilitation of GABA [59].
Studies from Shahidi et al. [50] indicated for the first time that the antinocicep-
tive effects of V. officinalis are mediated by the serotonergic and dopaminergic systems.
Monoamine neurotransmitters in the central nervous system, mostly serotonin
(5-hydroxytryptamine, 5-HT) and norepinephrine, are crucial in regulating cognition,
emotion, and mood. These neurotransmitters also play an essential role in the stress
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response and the mechanism of antidepressant action. It was observed that V. officinalis ex-
tract can suppress physical and psychological stress responses by controlling the variations
in these neurotransmitters turnover in the hippocampus and amygdala [22], and reduces
the plasma corticosterone levels in D-galactose-induced aging mice [49]. Dichloromethane
extracts from V. wallichii significantly improve norepinephrine and dopamine amounts with
no changes in serotonin amounts [59]. The effects of V. adscendens extracts on the central
nervous system have been associated with the interaction with serotoninergic, dopamin-
ergic, and noradrenergic receptors [95]. On the other hand, studies from Lee et al. [39]
suggest that the antinociceptive effects of V. fauriei can be related to modulatory effects on
the BDNF signaling pathway in the hippocampus and medial prefrontal cortex. Recently,
Choi et al. [96] demonstrated that this species exerts antidepressant effects through its
anti-inflammatory and antioxidant effects by inhibiting BDNF expression.
Valepotriates from V. jatamansi inhibit Cav2.2 and Cav3.1 calcium channels in a se-
lective way which is coherent with the analgesic action of this species in relieving gas-
trointestinal and rheumatic pain [97]. Moreover, studies by Dong et al. [98] indicated that
its use for alleviating abdominal distention and pain may be mediated through Cav2.2
channel. Although the information about the anticonvulsant effects of valerian is scarce,
studies from Rezvani et al. [63] suggested that it is mediated through the activation of the
adenosine system.
Santos et al. [54] demonstrated that different compounds from V. officinalis extract
may trigger distinct mechanisms involved in neuronal cell protection in PD. Hesperidin,
and probably linarin, alleviate oxidative stress effects during ATP depletion due to its
capability to binding SUR1. On the other hand, valerenic acid and apigenin avoid cortical
hyperexcitation by stimulating neuronal cells from the substantia nigra to release GABA
on the brain stem. V. amurensis showed protective effects on amyloid-beta (Aβ)-induced
toxicity in PC12 cells [99] and capacity to improve Aβ-induced cognitive dysfunction
in mice by two mechanisms, by enhancing acetylcholine and choline acetyltransferase
activity and thus improving cerebral cholinergic function, and by protecting neurons from
Aβ-induced apoptosis [35].
The anti-neuroinflammatory effects of N. jatamansi extracts and isolated compounds
have been described by different authors. Ko et al. [83] reported that four nardosinone-
type sesquiterpenes showed anti-neuroinflammatory action on lipopolysaccharide (LPS)-
induced immortalized murine brain microglia BV2 cell lines by inhibiting NF-κB- and
MAPK-mediated inflammatory pathways. The anti-neuroinflammatory effects of two
sesquiterpenoids from this species, desoxo-narchinol A and narchinol B, in BV2 and the
primary microglial cell, was also reported, which is related to the inhibition of LPS-induced
expression of iNOS and COX-2 enzymes the suppression of pro-inflammatory cytokines
(IL-1b, IL-6, and TNF-a). Yoon et al. [33] showed that the inhibition of the NF-κB signaling
pathway was also implicated in the anti-neuroinflammatory effect of three sesquiterpenoids
from this species. Recently, Kim et al. [84] reported the anti-neuroinflammatory effect of
desoxo-narchinol A and narchinol B in microglial cells by up-regulating of nuclear tran-
scription factor erythroid-2-related factor 2/heme oxygenase-1 signaling. The mechanisms
of action of Valerianaceae plants have not been fully investigated in humans. The effects
of V. officinalis extract on cortical excitability were evaluated in humans with transcranial
magnetic stimulation [100] and it was observed that a single oral dose adjusts intracortical
facilitatory circuits.
5. Other Pharmacological Potential of Valerianaceae
As aforementioned some Valerianaceae species, particularly from the Valeriana genus,
are well investigated for their pharmacological potential on the central nervous, namely
anxiolytic, antidepressive, antinociceptive, and anticonvulsant, etc. However, various Vale-
riana species are still understudied for other biological properties. Among all the species,
V. officinalis, V. jatamansi (syn. Valeriana wallichii), V. hardwickii Wall, and V. stenoptera Diels.
are the ones that show better potential for further investigation in drug discovery. The
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bioactivity of root extracts from V. officinalis is mainly associated with its anxiolytic com-
pounds, as the valerenic acid and its biosynthetic precursors, valerenal and valerenadiene.
β-Caryophyllene is another sesquiterpenoid present in the extracts but is more associated
with the anti-inflammatory effect, and in this case, V. officinalis and V. wallichii still need
to be more deeply studied. Regarding anti-viral, hepatoprotective, or immune stimulant
activities, no relevant data was found in the last ten years. The most recent research with
Valeriana spp. is published in anti-anxiety, anti-bacterial, anti-cancer, anti-depressive, and
cardiovascular effects, and they are summarized below for a better understanding of the
data available.
5.1. Antibacterial Effect
Regarding the antibacterial activity of Valeriana spp. extracts few data are avail-
able [101]. The aerial parts of V. wallichii DC (Valerianaceae) were evaluated by Khuda
et al. [101], for their antifungal and antibacterial activities. The authors prepared two
extracts with the aerial parts of the plant, one with chloroform and the other with hexane,
and both showed significant bioactivity [101]. It was also reported antibacterial activity for
Staphylococcus aureus and Pseudomonas aeruginosa by four sesquiterpenoids isolated from
the roots of V. jatamansi Jones [102].
5.2. Anti-Cancer Effect
Current pharmacotherapy has critical tools to speed the development of new target
therapies which will accelerate the final goal in the fight against cancer. Various compounds
separated from V. jatamansi and V. officinalis roots were active for a variety of cellular cancer
lines, both in vitro and in vivo assays. For instance, among the isolated constituents from
V. jatamansi, the derivative IVHD-valtrate, is one of the most promising molecules that was
tested against human ovarian cancer cells (A2780 and OVCAR-3), in vitro and in vivo. This
compound showed inhibition of the growth and proliferation in a concentration-dependent
manner. This compound also revealed low cytotoxicity to immortalized non-tumorigenic
human ovarian surface epithelial cells (IOSE-144), which is very important for further
research. The authors even refer that Preclinical results pointed out IVHD-valtrate as a
potential therapeutic drug for this type of cancer [103].
Two years late, the same group evaluated jatamanvaltrates P-Y, nardostachin, and
ten new valepotriates, but this time, the compounds were isolated from the whole plants
and found cytotoxic activity against PC-3M cells [104]. They also examined the structure-
activity relationship of these valepotriates and the results reveal a crucial 10-chlorine in
the oxirane ring and the bond C3–C4. The compound valtrate was able to avoid migration
of human breast cancer cells and induce apoptosis, both in vitro and in vivo. In another
experiment, they discover that valtrals (A, B, and C), which are by-products of valepotriates
resulting from a degradation reaction during the separation methodology from the ethanol
extract prepared with the entire plant, showed selective cytotoxicity against colon cancer
(HCT-8) cell lines and metastatic prostate cancer (PC-3M) [104]. Other tests performed
with three new minor valepotriate isomers, jatamanvaltrates, all of them isolated from the
entire plants of V. jatamansi, evidenced moderate cytotoxicity in the two cell lines cited
above and also hepatoma (Bel7402) [105]. Jatamanvaltrate P, an iridoid ester, can inhibit
the proliferation and growth, in a concentration-dependent manner, of MDA-MB-231,
MDA-MB-453, and MDA-MB-468 (this last three lines corresponding to the triple-negative
breast cancer) and MCF-7 cell lines. As the author’s highlight, this molecule exhibited an
antitumor effect in MDA-MB-231 xenografts without noticeable toxicity, suggesting that it
could be used in research for a future potential therapeutic drug against breast cancer [105].
A specific fraction obtained from V. jatamansi (no data provided about the parts of the
plant) significantly inhibited the growth of breast cancer cells in a concentration-dependent
manner by inducing apoptosis [106]. Among its therapeutic effects on insomnia and
seizures the valeric acid, which is another active compound in valerian, has been reported
to improve immunity against cancer [107]. Promising data also involve other compounds,
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in this case, fatty acids naturally occurring in seed oils such as conjugated linolenic acids
(CLNs) which are likewise present in C. ruber and V. officinalis) [108].
5.3. Anti-Inflammatory Effect
Cravotto, et al. [109] summarized the available scientific information on the intense,
in-progress investigation for novel plants, extracts, and compounds with intense anti-
inflammatory activity and found out that V. officinalis has, among many others understudy,
this potential too. Other species like V. jatamansi Jones also presented this bioactivity [70].
There is also a report on the anti-inflammatory activity, of a methanolic crude extract
prepared from V. wallichii leaves (topical formulation cream) using an in vitro and in vivo
screening. The authors presented data of a considerable in vitro anti-inflammatory activity
obtained with the ethyl acetate fraction [110].
5.4. Antioxidant Effect
In natural products, different compounds are under screening for their antioxidant
activity and the possible use for therapeutic strategies, for instance in degenerative dis-
eases. Among the various therapeutic properties attributed to Valeriana spp., most of them
correlated to valepotriates, the antioxidant properties were also investigated. According
to Sudati et al. [111], V. officinalis extracts show a protective effect on lipid peroxidation
(LPO) caused by different pro-oxidant reactive with neuro damage relevance. Dugaheh
et al., [112] also studied the antioxidant effect of root extracts from V. officinalis, N. jatamansi,
and V. sisymbriifolia. The best DPPH inhibition effect was obtained with V. officinalis extracts,
but all of the tested plants inhibited beta-carotene oxidation.
Another antioxidant activity investigation carried out with the aerial parts and roots of
V. jatamansi, collected in pre-flowering, flowering, and post-flowering phenological stages,
pointed to higher results for the first one, which could be correlated to the maximum
concentration of phenolics and flavonoids. These methanolic extracts include catechin,
and various phenolic acids as gallic, chlorogenic, hydroxybenzoic, caffeic, and p-coumaric,
which largely varied among the different phenological stages, and along the altitudes.
It was also highlighted that the pre-flowering stage is the most suitable for harvesting the
roots containing the maximum phytochemicals amounts and antioxidant activity even for
the samples which have few phenolics as the ones collected at high altitudes [113].
5.5. Cardiovascular Effect
Cardiovascular diseases are an important cause of death worldwide. Much research
has been conducted to treat and delay these pathologies; however, much more needs to be
done.
According to a report, lowering of blood pressure and heart rate, antiarrhythmic, reg-
ulation of blood lipid levels, and anti-myocardial ischemia-reperfusion injury are bioeffects
that can be attributed to Valeriana spp. them. The vasorelaxant effect in endothelium-
denuded rings was obtained with a hexane extract from V. edulis. The authors speculate
that this effect could be related to the presence of valepotriates obtained from the hexane
extract rhizomes [11]. It was suggested by Gan et al. [114] that some plant extracts, com-
pared with the “model group”, could decrease the percentage of infarct volume, improve
neurological activity, accentuate the expression of VEGFR2 and number of new blood
vessels in the cortex infarction around, given a possible further use to relive the acute
cerebral ischemia-reperfusion injury [114].
6. Phytochemical Configuration of Valerianaceae
Different species under the sub-family Valerianaceae exhibits pharmacologic activities,
especially in the central nervous system. These plants are known sources of different
phytochemicals such as flavonoids, lignans, neolignans, and terpenoids [24,53,99,115].
Table 2 shows the various extraction methods and biological activities of compounds
isolated from selected species under the sub-family Valerianaceae.
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Phytochemical compounds from Valerianaceae have great potential as drugs for neu-
rodegenerative diseases (Figure 1). The compounds (–)-(8R)-neonardochinone A, (+)-(8S)
neonardochinone A, and nardochinins A–D isolated from N. jatamansi exhibit anti-AD activ-
ity using the humanized Caenorhabditis Elegans AD pathological model [115]. Lignans and
iridoids isolated from V. amurensis showed neuroprotective activity against Aβ-induced
toxicity in PC12 cells [35,99,119]. AD is associated with the production and deposition of
the β-amyloid peptide (Aβ) in the brain [23]. Several compounds isolated from V. jatamansi
such as jatadoids A and B, jatairidoids A and B, valeriandoids A–C, chlorovaltrate, valeri-
lactones A and B, and bakkenolide-H have been studied to have neuroprotective properties
in MPP+-induced Parkinson’s disease model in vitro [43,44,105,127]. Sesquiterpenoids
from V. officinalis showed AChE inhibitory activity in vitro [53,131]. AChE inhibitors are
clinically used to treat neuropsychiatric symptoms of AD, PD, dementia, and schizophrenia.
These compounds are promising lead compounds for discovering drugs for AD and PD.
The other compounds from Valerianaceae are also known for their relaxant effects.
Aristolen-1(10)-en-9-ol, calarene, β-maaliene, and valerena-4,7(11)-diene isolated from
N. jatamansi showed significant sedative effects in mice studies [28,75,76,116]. Treatment
with valerena-4,7(11)-diene prolonged the continuous sleep time of pentobarbital-treated
mice by about 2.7 times [116]. Aristolen-1(10)-en-9-ol also exhibited a sedative effect com-
parable to that of diazepam and this sedative property is mediated through the GABAergic
system [76]. Acetoxyvalerenic acid, valerenic acid, and linarin from V. officinalis also showed
sedative and sleep-enhancing properties in animal studies [25,128]. 2S(−)-hesperidin, 6-
methylapigenin isolated from V. jatamansi also showed sedative properties while valtrate
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exhibited anxiolytic effects and significantly reduced the corticosterone level in the rat
serum [24,124,126].
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The compounds isolated fro plants under sub-family Valerianaceae are also known
for their neuroprotective properties. Valeneomerin from V. officinalis showed neuropro-
tective properties against oxidative stress [130]. Different sesquiterpenes isolated from
N. jatamansi (isonardosinone, kanshone B, E, J, K, L and M, and nardosinone), P. scabiosi-
folia (caryophyllene oxide and V. amurensis (kissoone B) prevented neuroinflammation in
LPS-stimulated BV2 and primary microglial cells [34,36,83,118]. Neuroinflammation is
associated with multiple neurodegenerative diseases such as AD, multiple sclerosis, and
PD [133]. Isopatrinioside, valeriananoid F, and structural analogs of chlorovaltrate isolated
from V. jatamansi exhibited neuroprotective properties against CoCl2-induced neuronal
cell death in PC12 cell [105,123]. These compounds may be further developed to prevent
chemical hypoxia-induced neurotoxicity.
Some compounds are also studied for their anticonvulsant, antidepressant, and stress-
reducing properties. Monoterpenoids from V. glechomifolia and sesquiterpenoids from
V. fauriei showed antidepressant activity in mice [37,41]. Valerena-4,7(11)-diene from
N. jatamansi reduced stress in animal studies [28]. Valepotriates from V. jatamansi and val-
trates from V. laurifolia showed anticonvulsant properties in mice [122,132]. These studies
show the variety of phytochemical compounds isolated from plant species under the sub-
family Valerianaceae. Interestingly, several compounds from subfamily Valerianaceae were
more associated with a certain biological effect in the central nervous system. Sesquiter-
penoids such as kanshone, kissoone, nardosinone, valerinic acid, etc., were shown to have
anti-neuroinflammatory properties and sedative effects. Flavonoids such as linarin and
methylapigenin were known to have sedative effects. On the other hand, monoterpenoids
and glycosides were shown to have neuroprotective properties against oxidative stress
and toxicants in neural cell lines. These compounds have huge potential to be developed
as preventive and therapeutic interventions for different diseases of the CNS. Most of the
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studies for these compounds are still currently in the preclinical phase and warrant more
clinical studies in the future.
7. Extraction and Isolation Procedure of Major Compounds from Valerianaceae
To ensure the reliability and replicability of preclinical studies using compounds from
plants under the sub-family Valerianaceae, standardization of plant collection and iden-
tification; phytochemical compounds extraction, isolation and validation are warranted.
Generally, plants undergo several processes before a pure compound can be isolated. This
includes collection and authentication of the plant, extraction, purification, and structure
determination. All the studies that were reviewed in this manuscript have utilized the
roots and the rhizomes of the plant as the main source for the crude extract and the isola-
tion of its potent pure compound. Extraction, fractionation, and purification of the roots
and rhizomes of Valerianaceae have no difference as compared to other plant extraction.
Each roots and rhizomes undergo air-drying, soaking, and chromatographic fractionation
and purification. This is a general method in all natural products research to extract all
the possible compounds within the plant. The roots and rhizomes are typically used for
medicinal purposes because it is believed that the essential oils from its roots produce the
biologic activity [134,135]. However, the use of roots and rhizomes is more destructive for
the plants than collecting their leaves and flowers or buds [136]. It was reported that in the
North-West Himalayan region, the population diversity of V. jatamansi is getting low. In
the North-East Himalayan region, this herb is also classified as an endangered medicinal
plant [137]. This requires a rigorous conservation measure to preserve these plants for
future research and medicinal use.
For the extraction process of biologically active compounds from plants under the sub-
family Valerianaceae, Figure 2 shows the schematic diagram. The roots and the rhizomes
were usually air-dried at room temperature. Some of the air-dried samples were further
macerated and pulverized for greater absorption of the solvent. Air-dried plant samples
were extracted with ethanol, methanol, hexane, and water solvent and underwent solvent
partitioning with a range of nonpolar to polar solvents such as ether, ethyl acetate, and
butanol. Most authors initially extracted the pulverized sample using an alcohol solvent
such as ethanol or methanol because these are the most polar among the non-polar solvents
and can extract several compounds [138]. Moreover, solvents such as water, methanol,
butanol, ethyl acetate, and ether were used for solvent partitioning. This is because
the compounds extracted have different polarity and solubility and through this range of
solvents can a researcher identify the most active compound. The most common compound
isolated belongs to the group of terpenoids. Most terpenoids are non-polar and volatile,
thus, solvent partitioning involving this range of non-polar to polar solvents is important
to isolate and purify the potent compound [134].
Each crude extract underwent a purification process through different chromato-
graphic techniques such as the use of silica gel column chromatography, thin-layer chro-
matography (TLC), and preparative high-performance liquid chromatography (HPLC).
TLC is commonly done among natural products research. It is the simplest and cheapest
technique to separate several components in an extract and verify the identity and purity
of the compound. Furthermore, TLC serves as a guide in setting the parameters for column
chromatography as a means for preparative separation [139]. Meanwhile, column chro-
matography is widely used as an initial separation step for the phytochemical components
because of its simplicity, high capacity, and low cost. In column chromatography, the
mobile phase carries the bioactive components as they pass through the stationary phase
that separates the components depending on their affinity [140]. HPLC, on the other hand,
is an analytic technique used to separate, quantify, and identify inorganic and organic
solutes. This technique is robust and versatile that requires high pressure to elute the
analyte to the detector [141]. In isolating iridoids, it was noted that these three common
techniques of purification: preparative TLC, silica gel CC, and preparative HPLC were
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used. It is a traditional way and more feasible way to isolate compounds before undergoing
more advance chromatographic techniques.
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As the solute is purified, the compound is identified through its structure and molec-
ular weight. Some of the techniques used to det rmine the structure of the pure com-
po nd responsible for its biological activity are nuclear magnetic resonance (NMR), gas
chromatography-mass spectr photometry (GC-MS), high-resolution electrospray ioniza-
tion ss spectrophotometry (HRESIMS), Fourier transform infrared sp cop (FT-IR),
and circular dichroism (CD). Each one has its advan age over the other but they help each
other in understanding more about the discovered compound. NMR is used to give an idea
about physical, chemical, and biol gical property of the compound through the identi-
fication of carbon present in t compou while MS is used o identify, quantify, elucidate
t structure, and dete mi e the molecular weight of the unknown comp und [142]. M ss
spectrometry is an analytical tool that can give qualitative and quantitative data about the
analyte and it ha everal types. O e of these is HRESIMS which is a robust technique
that can an lyze t minute volume of samples that are non-volatile and thermally stable
c mpounds. It is used when conventio al techniques cannot analyze the gi en sample
while GC-MS is a combination of two techniques making it a powerful tool in the analysis
of a certain compound [143]. Gas chromatography separates the individual components
while mass spectrometry characterizes the components. On the other hand, FTIR is a tool
to identify the functional groups and the structure of the molecule in a given extract [142].
Finally, the CD is absorption spectroscopy that uses circularly polarized light to determine
the chirality of a given compound [144]. Therefore, there is no single process in doing natu-
ral product research. The process always depends on the characteristic of the compound to
be discovered.
8. Preclinical and Clinical Effectiveness in Humans and Patents
Although valerian has traditionally been used as a mild sedative, research results are
still controversial today regarding the role of the different active compounds, the herbal
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preparations, and the dosage used [24,145]. In fact, in vivo studies, showed that valerian
can be used as an anti-depressant [92,146] (Table 3). In particular, as abovementioned the
neurobiological mechanisms of the different bioactive compounds in Valerianaceae species
can be due to the effects on GABA, serotoninergic, dopaminergic, noradrenergic, and adeno-
sine A1 receptors [86,95,147,148]. V. glechomifolia extract containing 96% of valepotriates
(10 mg/kg) showed anxiolytic and sedative properties reducing exploratory and behavior
locomotion during open field exploration without affecting memory test. Otherwise the
dose of 3 mg/kg V. glechomifolia selectively influenced the recognition memory without
effects on other behavioral parameters [149]. The anti-depressant activity of V. glechomifolia
in mice also appears to be due to the interaction with noradrenergic and dopaminergic
neurotransmission. The extract of V. glechomifolia can enhance its antidepressant effects
such as imipramine, desipramine, and bupropion without involving the neurotransmission
of serotonin and activating the noradrenergic and dopaminergic systems [149]. Holzamann
et al. [58] reported the general depressive activity in rats Wistar treated with 50–150 mg/kg
p.o. of the extract of V. prionophylla Standl., used in Mesoamerican traditional medicine for
treating sleep disorders. This effect seems to be related to the capacity of V. prionophylla to
increase pentobarbital-induced sleep time and to decrease sleep latency [150].
Table 3. In vivo studies on the effects of some species belonging to the Valerianaceae sub-family on
the Central Nervous System.
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V. jatamansi Kunming mice Ethanolic extract Anxiolytic effects; Nodrug dependence [146]
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V. edulis Wistar male rats 2.5 mg/10 g; 5mg/10 g
Anticonvulsant
properties [156]
The anxiolytic, sedative, and memory effects of extracts from Valerianaceae species
may be due to the ability to interact with the GABAA receptor, possibly at the level of the
subtypes (sub-unit β3; GABRB3) of receptors that mediate the effects of benzodiazepines,
so producing the hypnotic and sedative activities. Administration of V. officinalis extracts at
different dosages in BALB/c mice is related to changes in the levels of the GABRB3 protein.
In particular, the extract induced an increase in the protein expression in comparison to
the group of animals, which were given diazepam [155]. The anxiolytic effects have also
been attributed to V. jatamansi; these effects may be due to the modulation of the levels
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of 5-HT, norepinephrine, dopamine, γ-aminobutyric acid, which by adjusting the axis
hypothalamus-pituitary-adrenal axis employing β-endorphins and corticosterone [146].
The sedative and anticonvulsant effects of V. edulis and several valerian extracts
are often related to high dosages and the different phytochemical compounds such as
valerenic acids and flavonoids, present in the different Valerian species. In vivo experi-
mental models confirmed that valerenic acid and valerian extracts have shown sedative
effects [151,156–158]. In particular, Benke et al. [152] recently demonstrated a precise
binding site on GABAA receptors that showed a high affinity for valerenol and valerenic
acid. Several previous studies demonstrated that the properties of valerian are related not
only by the interaction with GABAA receptors but also by the involvement of adenosine
receptors [148,159,160].
Several authors reported that the administration of valepotriates or V. officinalis root
extracts in zebrafish larvae induced the modulation of c-fos and of Npas4a, involved in
regulating of the neural circuits [154,161–163]. The modulation of these genes, induced by
valepotriates, together with their ability to bind GABAA receptors and histone deacetylase
(HDAC) inhibitors confirm the neuroprotective effects of valerian extracts [164]. In addition
to their anxiolytic and depressive effects, the extracts from V. officinalis can protect the
neurons of the hippocampus from ischemic damage and restore behavioral deterioration.
These protective effects are due to the ability of V. officinalis and its main constituents
such as valerenic acid and acetylvalerenolic acid, to inhibit the activity of the nuclear
factor (NF)-κB in vitro [165]. Other studies showed that the CNS effects of V. officinalis,
V. jatamansi, and N. jatamansi can certainly also attributed to the inhibitory activity exerted
on AChE [166].
Rahman and collaborators showed that the administration of an N. jatamansi ethanol
extract to young and aged mice for 8 days enhanced memory and learning and determined
a reversion of the amnesia induced by diazepam and scopolamine [153]. Among the
Valerianaceae sub-family, few species have been clinically evaluated for their biological
activities on CNS, despite the large traditional use, to treat insomnia, anxiety, epilepsy,
and neurodegenerative diseases. The majority of controlled clinical trials available in the
scientific literature are on the efficacy of improving sleep disorders of different valerian
extracts. A fact sheet from the NIH Office of Dietary Supplements updated on March
2013 [167] is reported five rated randomized, controlled trials (Table 4).
The studies showed that V. officinalis root improved sleep quality [168], reduced sleep
latency and improved the subjective sleep rating [169], decreased insomnia symptoms [170]
and also improved sleep quality with results comparable to those obtained by the admin-
istration of 10 mg of oxazepam but with fewer side effects [171]. Conversely, subsequent
randomized double-blind studies based on sleep parameters evaluated objectively with
polysomnographic techniques detected no substantial differences on any of the measure-
ments in comparison to the placebo group except for only one parameter [172]. The NHI
document addressed to health professionals, concluded that qualitative results suggest that
V. officinalis would be a promising strategy for insomnia and sleep-associated disorders
subjective improvement. However, not all studies have produced positive outcomes and
the real effectiveness of V. officinalis could not be proved by objective or quantitative mea-
surements due to methodological limitations observed in most clinical studies, such as the
small sample sizes, the unstandardized sources of valerian, the low rate of reproducibility
of the results, etc.
Recently, Shinjyo et al. [173], based on a systematic review of 60 studies and meta-
analyses, updated and re-evaluated the most reliable literature data to assess the effective-
ness of V. officinalis in ameliorating sleep and sleep-associated disorders, yet controversial
and not fully conclusive. The authors reported that the inconsistent and conflicting results
of the clinical trials are maybe due to the quality and to the differences in herbal preparation
in addition to the aforementioned methodological limits verified.
Plants 2021, 10, 846 21 of 29
Table 4. Systematic reviews reporting the effectiveness of some species of Valerianaceae sub-family
on CNS.
Species SystematicReview Indication Conclusions Source









quality control is needed
[173]







Among the 40 articles analyzed to assess the effectiveness of V. officinalis to treat sleep
disorders, 30 addressed its efficacy in ameliorating sleep quality and sleep-associated
problems. The additional analysis of seven articles also revealed the efficacy of V. officinalis
in inducing positive effects on anxiety states in different stress conditions, also confirmed
by another recent study on its anxiolytic activity in patients during dental surgery [174].
Other positive effects are reported in reducing the symptoms of obsessive-compulsive
disorder and in preventing cognitive dysfunction rather than in reducing menopausal and
postmenopausal hot flashes in women. Concluding, the results of this study suggested that
the whole root rather than different extracts of V. officinalis is a valid and safe alternative
for the treatment of sleep problems and anxiety. V. wallichii and V. edulis rich only in
valepotriates and lacking in valerenic acids demonstrated sleep-promoting properties but
the numbers of the studies are insufficient. The therapeutic effects on sleep were found
with the use of doses of 450–1410 mg of the whole root per day for up to 8 weeks. These
positive biological activities could be ensured by the standardization and characterization
of the phytochemical profile of the diverse active compounds present in extracts and could
be improved by the combination with different sleep-promoting herbs [173]. N. grandiflora
is another species tested in a preliminary clinical study; the principle compound jataman-
sone obtained from the rhizomes significantly reduced aggressiveness and restlessness in
hyperkinetic children [153].
Most common commercial Valerian preparations are generally quite safe for short-
term use (for 4–6 weeks), 600 mg of valerian did not cause clinically significant effects on
reaction time, alertness, and concentration the morning after ingestion [167]. No literature
data is available that demonstrated the safety of long term use. In addition, little is known
about their use in the woman during pregnancy and nursing and in children younger
than 3 years old. However, the few side effects reported in the literature include agitation,
restlessness, insomnia, headache, dizziness, itching and gastrointestinal upset. Particular
attention must be paid to the potential interactions with sedative substances such as
barbiturates, benzodiazepine, melatonin, alcohol, some herbs and dietary supplements
with sedative properties (Hypericum perforatum L., Piper methysticum G. Forst) due to the
potential additive effects. Cytotoxicity was detected only in vitro for valepotriates with
no carcinogenic effects in animal models. These compounds are not always present in
commercial valerian preparations. There is report that the roots and rhizomes of Valeriana
officinalis have been used in official medicine in the form of various dosage for more
than 240 years [175]. Moreover, Valeriana drugs in Russian medicine are used in mono
form, which increases the importance of this plant for the treatment of a wide range of
diseases [175]. Despite the wide use of these herbs in traditional medicine as well in
the official medicine, more advanced clinical studies are still necessary on other plant
species of this subfamily to establish the numerous biological activities associated with
their pharmacological applications.
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9. Conclusions
The studies reported and discussed in the present review article have indicated
the multifaceted biological activities of many species from the Valerianaceae sub-family.
Reviewed studies indicated that species from the genus Valeriana, particularly species like
V. officinalis, V. jatamansi, V. fauriei, V. amurensis, V. glechomifolia, and V. polystachya have
positive effects to treat disorders related to the Central Nervous System dysfunctions, such
as insomnia, anxiety, and epilepsy. The mode of action of valerian compounds is mainly
associated with the modulation of GABAergic transmission. Nevertheless, validated
clinical studies are still necessary to establish the numerous and interesting biological
activities associated with the pharmacological applications of the species.
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